Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €0.34 EUR
Change Today -0.002 / -0.58%
Volume 1.5M
PHARM On Other Exchanges
Symbol
Exchange
EN Amsterdam
OTC US
Frankfurt
As of 11:35 AM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

pharming group nv (PHARM) Snapshot

Open
€0.35
Previous Close
€0.35
Day High
€0.35
Day Low
€0.34
52 Week High
07/17/14 - €0.65
52 Week Low
03/4/15 - €0.30
Market Cap
140.4M
Average Volume 10 Days
1.9M
EPS TTM
€-0.01
Shares Outstanding
408.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PHARMING GROUP NV (PHARM)

Related News

No related news articles were found.

pharming group nv (PHARM) Related Businessweek News

No Related Businessweek News Found

pharming group nv (PHARM) Details

Pharming Group N.V. develops, produces, and commercializes human therapeutic proteins for unmet medical needs. It is involved in the production, purification, formulation, and development of recombinant protein products. The company offers Ruconest (conestat alfa), a recombinant human C1 esterase inhibitor approved for the treatment of angioedema attacks in patients with hereditary angioedema in European Union countries, Norway, Iceland, and Liechtenstein. It also engages in the development of recombinant human C1 inhibitor (rhC1INH) for ischemia-reperfusion injury (IRI) indications, including myocardial infarction, stroke, and delayed graft function in transplantation; and rhFactor VIII for Haemophilia A. The company has a strategic collaboration with Shanghai Institute of Pharmaceutical Industry for the development, manufacture, and commercialization of new products based on the Pharming technology platform. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

53.8 Employees
Last Reported Date: 03/18/15

pharming group nv (PHARM) Top Compensated Officers

Chief Executive Officer and Member of Managem...
Total Annual Compensation: €624.0K
Chief Operations Officer and Member of Manage...
Total Annual Compensation: €391.0K
Compensation as of Fiscal Year 2014.

pharming group nv (PHARM) Key Developments

Pharming Group NV Presents at BioCapital Europe 2015, Mar-26-2015 04:20 PM

Pharming Group NV Presents at BioCapital Europe 2015, Mar-26-2015 04:20 PM. Venue: Sofitel Legend Amsterdam, Amsterdam, Netherlands.

Pharming Group NV Announces the Nominations of Paul Jai Sekhri and Jan Hendrik Egberts as Members of its Board of Supervisory Directors

Pharming Group N.V. announced the nominations of Paul Jai Sekhri and Jan Hendrik Egberts as members of its Board of Supervisory Directors. The nominations will be subject to shareholders' approval at the upcoming Annual General Meeting of Shareholders, which will take place on 30 April 2015. Mr. Sekhri has over 28 years of operational experience in life sciences with in-depth knowledge of multinational pharmaceutical and biotechnology markets and products. Mr. Egberts has over 25 years of executive experience in the pharmaceutical and medical device sectors, most recently as Chief Executive Officer at Agendia Inc.

Pharming Group NV Announces Earnings Results for the Full Year Ended December 31, 2014

Pharming Group NV announced earnings results for the full year ended December 31, 2014. For the year, the company reported revenues of €21,186,000 compared with €6,844,000 for the same period a year ago. Operating profit was €2,877,000 compared with operating loss of €6,912,000 for the same period a year ago. Loss before tax was €5,767,000 compared with €15,060,000 for the same period a year ago. Net loss for the year from continuing operations was €5,767,000 or €0.014 per basic share compared with €15,060,000 or €0.071 per basic share for the same period a year ago. Net loss for the year attributable to owners of the parent was €5,767,000 compared with €15,060,000 for the same period a year ago. Net cash used in operating activities was €2,573,000 compared with €8,293,000 for the same period a year ago. Purchases of property, plant and equipment was €185,000 compared with €21,000 for the same period a year ago. Purchases of intangible assets was €469,000.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PHARM:NA €0.34 EUR -0.002

PHARM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ablynx NV €9.53 EUR -0.018
BioCryst Pharmaceuticals Inc $9.78 USD 0.00
Oxford Biomedica PLC 12.50 GBp +0.25
Shire PLC 5,430 GBp -30.00
View Industry Companies
 

Industry Analysis

PHARM

Industry Average

Valuation PHARM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.9x
Price/Book 4.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PHARMING GROUP NV, please visit www.pharming.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.